Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127105561 | 12710556 | 1 | I | 20141120 | 20160825 | 20160902 | 20160902 | EXP | IT-ASTRAZENECA-2016SE92278 | ASTRAZENECA | 26167.00 | DY | F | Y | 0.00000 | 20160902 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127105561 | 12710556 | 1 | PS | ROSUVASTATIN. | ROSUVASTATIN | 1 | Oral | Y | U | 21366 | TABLET | ||||||||
| 127105561 | 12710556 | 2 | SS | ROSUVASTATIN. | ROSUVASTATIN | 1 | Oral | REDUCE UP TO 3 MG | Y | U | 21366 | TABLET | |||||||
| 127105561 | 12710556 | 3 | SS | PRAVASTATIN. | PRAVASTATIN | 1 | Unknown | Y | U | 0 | |||||||||
| 127105561 | 12710556 | 4 | SS | PRAVASTATIN. | PRAVASTATIN | 1 | Unknown | REDUCE UP TO 3 MG | Y | U | 0 | ||||||||
| 127105561 | 12710556 | 5 | C | ABSORCOL (EZETIMIBE) | 2 | 10.0MG UNKNOWN | 0 | 10 | MG | TABLET | |||||||||
| 127105561 | 12710556 | 6 | C | ABSORCOL (EZETIMIBE) | 2 | REDUCE UP TO 3 MG UNKNOWN | 0 | TABLET | |||||||||||
| 127105561 | 12710556 | 7 | C | LASIX | FUROSEMIDE | 1 | 0 | ||||||||||||
| 127105561 | 12710556 | 8 | C | LASIX | FUROSEMIDE | 1 | REDUCE UP TO 3 MG | 0 | |||||||||||
| 127105561 | 12710556 | 9 | C | BISOPROLOL | BISOPROLOL | 1 | 0 | ||||||||||||
| 127105561 | 12710556 | 10 | C | BISOPROLOL | BISOPROLOL | 1 | REDUCE UP TO 3 MG | 0 | |||||||||||
| 127105561 | 12710556 | 11 | C | LERCANIDIPINE | LERCANIDIPINE | 1 | 0 | ||||||||||||
| 127105561 | 12710556 | 12 | C | LERCANIDIPINE | LERCANIDIPINE | 1 | REDUCE UP TO 3 MG | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127105561 | 12710556 | 1 | Hypercholesterolaemia |
| 127105561 | 12710556 | 2 | Hypercholesterolaemia |
| 127105561 | 12710556 | 3 | Hypercholesterolaemia |
| 127105561 | 12710556 | 4 | Hypercholesterolaemia |
| 127105561 | 12710556 | 5 | Hypercholesterolaemia |
| 127105561 | 12710556 | 6 | Hypercholesterolaemia |
| 127105561 | 12710556 | 7 | Hypertension |
| 127105561 | 12710556 | 8 | Hypertension |
| 127105561 | 12710556 | 9 | Hypertension |
| 127105561 | 12710556 | 10 | Hypertension |
| 127105561 | 12710556 | 11 | Hypertension |
| 127105561 | 12710556 | 12 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127105561 | 12710556 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127105561 | 12710556 | Blood creatine phosphokinase MB increased | |
| 127105561 | 12710556 | Myopathy | |
| 127105561 | 12710556 | Pain in extremity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |